RxDoctor Payments Data

Peter Kelly, MD

Internal Medicine · Coronado, CANPI 1265412779

Payments from drug & device makers

$530in general payments, 2019–2025

Across 17 payments — averaging $31.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$128
  • Intuitive Surgical$103
  • Lilly USA, LLC$51
  • Teleflex LLC$45
  • Novo Nordisk$33
  • Boehringer Ingelheim$31
  • plus $139 from 6 others

What the payments were for

  • Food & beverage$530100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$530 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$149,277
Medicare patients
476
Services billed
6,686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$64,850
JardianceEmpagliflozin30$48,367
OzempicSemaglutide22$40,059
TrulicityDulaglutide13$25,701
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,569
RytaryCarbidopa/Levodopa12$13,635
MyrbetriqMirabegron18$12,689
Atorvastatin Calcium206$2,846
Levothyroxine Sodium159$2,504
Candesartan Cilexetil16$2,244
Losartan Potassium140$1,803
Estradiol21$1,567
Tamsulosin Hcl106$1,537
PaxlovidNirmatrelvir/Ritonavir22$1,377
Lisinopril141$1,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$30$66,22791 claims
Boehringer IngelheimJardiance$31$48,36730 claims
Novo NordiskOzempic$33$40,05922 claims
Lilly USA, LLCTrulicity$51$25,70113 claims
GSKTrelegy Ellipta$31$15,56920 claims
Astellas Pharma US IncMyrbetriq$27$12,68918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Coronado

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →